Ascentage Pharma Group International has presented updated clinical data on Olverembatinib, its novel therapy for second-line treatment of chronic myeloid leukemia in chronic-phase (CML-CP), at the 67th American Society of Hematology $(ASH)$ Annual Meeting. The results showed a 76.7% complete cytogenetic response rate in patients who had failed first-line therapy with second-generation tyrosine kinase inhibitors (TKIs). Molecular responses deepened with extended treatment duration, with a major molecular response rate reaching 60% at 21 cycles. The company reported that the efficacy data support the potential for advancing Olverembatinib to earlier lines of treatment for a broader patient population. The findings presented were updates from results previously released at ASH 2024 and included longer follow-up data on efficacy and safety.